Pancreatic Cancer Research

ResearcherOslo University HospitalActive in the last 2 years

Dyre Berg Kleive

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7072-8422; OpenAlex author ID A5081812564. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 6 papers · 2026: 1 paper

Papers 13

  1. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  4. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  5. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  6. Anatomical Classification and Staging Systems of Borderline Resectable and Locally Advanced Pancreatic Cancer-A Subgroup Analysis of the NORPACT-2 Trial. Co-author DOI 10.1245/s10434-025-17527-y↗
  7. Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced … Co-author DOI 10.3390/cancers17152505↗
  8. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  9. The value of splenectomy during left-sided pancreatectomy for pancreatic ductal adenocarcinoma: predefined subanalysis in the DIPLOMA randomized trial. Co-author DOI 10.1093/bjs/znae236↗
  10. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  11. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective coho… First author DOI 10.1093/bjsopen/zrad137↗
  12. Is there a survival benefit of a robotic approach to pancreatoduodenectomy for pancreatic cancer? Co-author DOI 10.21037/hbsn-22-500↗
  13. Laparoscopic distal pancreatectomy for pancreatic ductal adenocarcinoma: Long-term oncologic outcomes after standard resection. Co-author DOI 10.1016/j.surg.2017.06.009↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Knut Jørgen Labori · 4 shared papers, 2017–2025 · strength 0.77
  2. Ingvild Farnes · 3 shared papers, 2023–2025 · strength 0.70
  3. Pål‐Dag Line · 3 shared papers, 2023–2025 · strength 0.70
  4. Caroline Sophie Verbeke · 3 shared papers, 2023–2025 · strength 0.70
  5. Sheraz Yaqub · 1 shared paper, 2023 · strength 0.31
  6. Kjetil Søreide · 1 shared paper, 2023 · strength 0.31
  7. Jacob Ghotbi · 1 shared paper, 2025 · strength 0.27
  8. Lars Aabakken · 1 shared paper, 2023 · strength 0.18
  9. Svein Dueland · 1 shared paper, 2023 · strength 0.18
  10. Matteo De Pastena · 1 shared paper, 2024 · strength 0.13
  11. Tobias Keck · 1 shared paper, 2024 · strength 0.13
  12. Svein Olav Bratlie · 1 shared paper, 2024 · strength 0.13
  13. David A. Kooby · 1 shared paper, 2024 · strength 0.13
  14. Riccardo Casadei · 1 shared paper, 2024 · strength 0.13
  15. Andrea Pietrabissa · 1 shared paper, 2024 · strength 0.13
  16. Bergþór Björnsson · 1 shared paper, 2024 · strength 0.13
  17. Adnan A. Alseidi · 1 shared paper, 2024 · strength 0.13
  18. Aleš Tomažič · 1 shared paper, 2024 · strength 0.13
  19. Izaak Quintus Molenaar · 1 shared paper, 2024 · strength 0.13
  20. John M. Primrose · 1 shared paper, 2024 · strength 0.13
  21. Safi Dokmak · 1 shared paper, 2024 · strength 0.13
  22. Maarten Korrel · 1 shared paper, 2024 · strength 0.13
  23. Giovanni Carlo Ferrari · 1 shared paper, 2024 · strength 0.13
  24. Thilo Hackert · 1 shared paper, 2024 · strength 0.13
  25. Patricia Sánchez‐Velázquez · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.